Moderna Snares $483 Million U.S. Funding for Covid Vaccine [Yahoo! Finance News]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance News
) -- Moderna Inc. said the U.S. government has agreed to pay as much as $483 million for the company to develop and test its Covid-19 vaccine now in an initial clinical trial.Under the agreement, the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, would fund development of the vaccine mRNA-1273 up through approval by the U.S. regulators, as well as efforts to scale up manufacturing, Moderna said in a press release.Moderna’s Covid-19 vaccine is one of the first to begin human trials. There are 70 vaccines in some stage of development now, the World Health Organization has said. Moderna said that if the trial is successful, it could reach final-stage testing by fall 2020.Vaccines give broad parts of the population some level of immunity to a disease, and are considered crucial to ending the pandemic by creating widespread immunity to the virus. They take longer to develop, in part because they must be proven to be extreme
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (NASDAQ:MRNA) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results [Yahoo! Finance]Yahoo! Finance
- The 20 stocks most shorted by hedge funds [Seeking Alpha]Seeking Alpha
- Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story [Seeking Alpha]Seeking Alpha
- Moderna (NASDAQ:MRNA) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- 1/5/26 - Form 8-K
- MRNA's page on the SEC website